Pharming Group N.V. (ETR:PHGN)

Market Cap	840.44M +47.9%
Revenue (ttm)	320.46M +15.2%
Net Income	10.72M
EPS	0.01
Shares Out	n/a
PE Ratio	78.42
Forward PE	20.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,612
Open	1.198
Previous Close	1.108
Day's Range	1.198 - 1.198
52-Week Range	1.056 - 1.780
Beta	n/a
RSI	44.53
Earnings Date	May 7, 2026

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 407
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PHGN

Financial Performance

Financial numbers in USD